Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma

Cancer Letters

Volumn 331, Issue 1, 2013, Pages 105-114

  Qu, Kai ^a   Xu, Xinsen ^a   Liu, Chang ^a   Wu, Qifei ^a   Wei, Jichao ^a   Meng, Fandi ^a   Zhou, Lei ^a   Wang, Zhixin ^a   Lei, Lei ^b   Liu, Peijun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Department of General Surgery   (China)

Author keywords

Cellular senescence; Forkhead box M1; Hepatocellular carcinoma; Oxaliplatin; P53

Indexed keywords

CYCLIN B1; CYCLIN D1; OXALIPLATIN; PROTEIN P21; PROTEIN P27; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SENESCENCE; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL AGING; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873522022     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.008     Document Type: Article

References (42)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
2. O'Suilleabhain C.B., Poon R.T., Yong J.L., Ooi G.C., Tso W.K., Fan S.T. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Brit. J. Surg. 2003, 90:325-331.
3. Burroughs A., Hochhauser D., Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004, 5:409-418.
4. Yen Y., Lim D.W., Chung V., Morgan R.J., Leong L.A., Shibata S.I., Wagman L.D., Marx H., Chu P.G., Longmate J.A., Lenz H.J., Ramanathan R.K., Belani C.P., Gandara D.R. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am. J. Clin. Oncol. 2008, 31:317-322.
5. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
6. Gewirtz D.A., Holt S.E., Elmore L.W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem. Pharmacol. 2008, 76:947-957.
7. Ozturk M., Arslan-Ergul A., Bagislar S., Senturk S., Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. Cancer Lett. 2009, 286:103-113.
8. Deocaris C.C., Widodo N., Shrestha B.G., Kaur K., Ohtaka M., Yamasaki K., Kaul S.C., Wadhwa R. Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett. 2007, 252:259-269.
9. Kim I.M., Ackerson T., Ramakrishna S., Tretiakova M., Wang I.C., Kalin T.V., Major M.L., Gusarova G.A., Yoder H.M., Costa R.H., Kalinichenko V.V. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006, 66:2153-2161.
10. Kalin T.V., Wang I.C., Ackerson T.J., Major M.L., Detrisac C.J., Kalinichenko V.V., Lyubimov A., Costa R.H. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006, 66:1712-1720.
11. Wang Z., Banerjee S., Kong D., Li Y., Sarkar F.H. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007, 67:8293-8300.
12. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., Aldape K.D., Xie T.X., Pelloski C.E., Xie K., Sawaya R., Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006, 66:3593-3602.
13. Li S.K., Smith D.K., Leung W.Y., Cheung A.M., Lam E.W., Dimri G.P., Yao K.M. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J. Biol. Chem. 2008, 283:16545-16553.
14. Park H.J., Carr J.R., Wang Z., Nogueira V., Hay N., Tyner A.L., Lau L.F., Costa R.H., Raychaudhuri P. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009, 28:2908-2918.
15. Zeng J., Wang L., Li Q., Li W., Bjorkholm M., Jia J., Xu D. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J. Pathol. 2009, 218:419-427.
16. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62:1876-1883.
17. Xia L., Huang W., Tian D., Zhu H., Zhang Y., Hu H., Fan D., Nie Y., Wu K. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J. Hepatol. 2012, 57:600-612.
18. Park S.H., Lim J.S., Jang K.L. All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27. Cancer Lett. 2011, 310:232-239.
19. Pandit B., Halasi M., Gartel A.L. P53 negatively regulates expression of FoxM1. Cell Cycle 2009, 8:3425-3427.
20. Millour J., de Olano N., Horimoto Y., Monteiro L.J., Langer J.K., Aligue R., Hajji N., Lam E.W. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol. Cancer Ther. 2011, 10:1046-1058.
21. Barsotti A.M., Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 2009, 28:4295-4305.
22. Wang I.C., Chen Y.J., Hughes D., Petrovic V., Major M.L., Park H.J., Tan Y., Ackerson T., Costa R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell Biol. 2005, 25:10875-10894.
23. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
24. Chang B.D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., Kandel E.S., Lausch E., Christov K., Roninson I.B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999, 59:3761-3767.
25. Fang K., Chiu C.C., Li C.H., Chang Y.T., Hwang H.T. Cisplatin-induced senescence and growth inhibition in human non-small cell lung cancer cells with ectopic transfer of p16INK4a. Oncol. Res. 2007, 16:479-488.
26. Wang X., Wong S.C., Pan J., Tsao S.W., Fung K.H., Kwong D.L., Sham J.S., Nicholls J.M. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res. 1998, 58:5019-5022.
27. Lim S.C., Choi J.E., Kang H.S., Han S.I. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int. J. Cancer 2010, 126:1582-1595.
28. Petros W.P., Broadwater G., Berry D., Jones R.B., Vredenburgh J.J., Gilbert C.J., Gibbs J.P., Colvin O.M., Peters W.P. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin. Cancer Res. 2002, 8:698-705.
29. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
30. Herbig U., Jobling W.A., Chen B.P., Chen D.J., Sedivy J.M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14:501-513.
31. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
32. Sun H.C., Li M., Lu J.L., Yan D.W., Zhou C.Z., Fan J.W., Qin X.B., Tang H.M., Peng Z.H. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol. Rep. 2011, 25:1533-1539.
33. Raychaudhuri P., Park H.J. FoxM1: a master regulator of tumor metastasis. Cancer Res. 2011, 71:4329-4333.
34. Park H.J., Gusarova G., Wang Z., Carr J.R., Li J., Kim K.H., Qiu J., Park Y.D., Williamson P.R., Hay N., Tyner A.L., Lau L.F., Costa R.H., Raychaudhuri P. Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol. Med. 2011, 3:21-34.
35. Frau M., Biasi F., Feo F., Pascale R.M. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol. Aspects Med. 2010, 31:179-193.
36. Laoukili J., Kooistra M.R., Bras A., Kauw J., Kerkhoven R.M., Morrison A., Clevers H., Medema R.H. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 2005, 7:126-136.
37. Wu Q.F., Liu C., Tai M.H., Liu D., Lei L., Wang R.T., Tian M., Lu Y. Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol. Sin. 2010, 31:361-366.
38. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
39. Chang B.D., Xuan Y., Broude E.V., Zhu H., Schott B., Fang J., Roninson I.B. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.
40. Kikuchi I., Nakayama Y., Morinaga T., Fukumoto Y., Yamaguchi N. A decrease in cyclin B1 levels leads to polyploidization in DNA damage-induced senescence. Cell Biol. Int. 2010, 34:645-653.
41. Majumder P.K., Grisanzio C., O'Connell F., Barry M., Brito J.M., Xu Q., Guney I., Berger R., Herman P., Bikoff R., Fedele G., Baek W.K., Wang S., Ellwood-Yen K., Wu H., Sawyers C.L., Signoretti S., Hahn W.C., Loda M., Sellers W.R. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14:146-155.
42. Lien W.H., Chen C.K., Lai L.Y., Chen Y.H., Wu M.P., Wu L.W. Participation of cyclin D1 deregulation in TNP-470-mediated cytostatic effect: involvement of senescence. Biochem. Pharmacol. 2004, 68:729-738.